Bluebird Bio (NQ: BLUE )

32.68 USD -0.30 (-0.91%)

Streaming Delayed Price Updated: 10:09 AM EDT, Jun 18, 2021 Add to My Watchlist

Price and Volume

Volume	48,692
Open	32.62
Bid (Size)	32.65 (3)
Ask (Size)	32.72 (1)
Prev. Close	32.98
Today's Range	32.52 - 32.82
52wk Range	24.24 - 68.39
Shares Outstanding	67,447,548
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented

June 11, 2021

bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the EU and UK) in adult, adolescent and...

bluebird bio to Present at Goldman Sachs Global Healthcare Conference

June 07, 2021

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference, Tuesday, June 8, at 8:50 a.m. ET.

Performance

YTD	-26.82%	-26.82%
1 Month	+6.55%	+6.55%
3 Month	+7.89%	+7.89%
6 Month	-26.99%	-26.99%
1 Year	-49.30%	-49.30%

More News

Interesting BLUE Put And Call Options For February 2022

Today 14:16 EDT

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

June 07, 2021

bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2021

Notable Monday Option Activity: BLUE, BIGC, GRPN

June 14, 2021

How The Parts Add Up: FBT Targets $202

June 11, 2021

bluebird bio Receives Positive CHMP Opinion for SKYSONA™ (elivaldogene autotemcel, Lenti-D™) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)

May 21, 2021

Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?

June 15, 2021

Long-Term Data from Pivotal KarMMa Study Continue to Demonstrate Deep and Durable Responses and Predictable Safety Profile with Bristol Myers Squibb and bluebird bio’s Abecma (idecabtagene vicleucel)

May 19, 2021

AavantiBio Rounds Out Leadership Team with Appointment of Jessie Hanrahan, Ph.D. as Chief Regulatory Officer

May 17, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.